

Monday 22 July 2024

Dear Doctor,

Availability of Kapanol® for treatment of severe pain and symptom reduction in chronic breathlessness¹

Mayne Pharma has received queries regarding the supply of KAPANOL (morphine sulfate pentahydrate) modified release capsules 10 mg, 20 mg, 50 mg and 100 mg, following the withdrawal notices for other products in this class. Mayne Pharma advises that KAPANOL remains available, with no anticipated shortages or supply issues.

KAPANOL¹:

- Indicated for the relief of chronic pain unresponsive to non-narcotic analgesia and symptom reduction of chronic breathlessness (CB) in palliative care patients.¹
- Once daily (every 24 hours) or twice daily (every 12 hours):
 - **PAIN** - The usual starting dose in opioid naïve patients is KAPANOL capsules 40 mg every 24 hours or 20 mg every 12 hours.¹
 - **CB** – Opioid naïve patients start 10 mg once daily. Review patients weekly. Maximum daily dose 30 mg.
- The capsule formulation contains **no immediate-release component** and delivers morphine with **minimal fluctuation** in the plasma concentrations.^{1,2}
- Available on the PBS.³

Please refer to the Product Information and Australian Government Prescription opioids: Information for health professionals before prescribing.⁴

If you would like further information on KAPANOL please email au.medical.information@maynepharma.com or call 1300 739 436. If you have questions on supply for your institution, please email au.enquiries@maynepharma.com.

Kind regards,



Debra Bourke
Head of Medical Affairs

Product Information available at: <https://www.ebs.tga.gov.au/Kapanol>

PBS Information:

Authority Required (Streamlined). For use in chronic severe disabling pain. The condition must be unresponsive to non-opioid analgesics.

Restricted Benefit. Chronic Breathlessness (patient must be receiving palliative care).



Mayne Pharma International Pty Ltd
ABN 88 007 870 984
maynepharma.com

T +61 3 8614 7777 F +61 3 9614 7022
Ground Level, 99 King Street, Melbourne, VIC 3000 Australia



You deserve tomorrow.

References: **1.** KAPANOL Approved Product Information. **2.** Gourlay GK, Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine, *Clin Pharmacokinet.*, 1998, 35(3):173-90.
3. <https://www.pbs.gov.au/medicine/item/11760Y-12501Y-8349K> [accessed on 15 July 2024]. **4.** [Prescription opioids: Information for health professionals | Therapeutic Goods Administration \(TGA\)](#) [Accessed on 15 July 2024].

KAPANOL® is a registered trademark of Mayne Pharma International Pty Ltd, ABN 88 007 870 984. 1538 Main North Road, Salisbury South, SA 5106. Telephone: 1300 081 849. KAP0016. Date of preparation: July 2024.